The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Whole-genome landscape of pancreatic neuroendocrine tumours
Abstract
The diagnosis of pancreatic neuroendocrine tumours (PanNETs) is increasing owing to more sensitive detection methods, and this increase is creating challenges for clinical management. We performed whole-genome sequencing of 102 primary PanNETs and defined the genomic events that characterize their pathogenesis. Here we describe the mutational signatures they harbour, including a deficiency in G:C > T:A base excision repair due to inactivation of MUTYH, which encodes a DNA glycosylase. Clinically sporadic PanNETs contain a larger-than-expected proportion of germline mutations, including previously unreported mutations in the DNA repair genes MUTYH, CHEK2 and BRCA2. Together with mutations in MEN1 and VHL, these mutations occur in 17% of patients. Somatic mutations, including point mutations and gene fusions, were commonly found in genes involved in four main pathways: chromatin remodelling, DNA damage repair, activation of mTOR signalling (including previously undescribed EWSR1 gene fusions), and telomere maintenance. In addition, our gene expression analyses identified a subgroup of tumours associated with hypoxia and HIF signalling.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“substitution signatures were dominated by C>A transversions in NpCpA or NpCpT contexts (Figures 2 and 3) previously associated with inactivation of the BER gene MUTYH [11].”
From Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers (2019) · cites this paper as [11]
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Self-citationIntratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
Law, C. W., Chen, Y., Shi, W., & Smyth, G. K. (2014) · Genome Biology · doi:10.1186/gb-2014-15-2-r29 · Cited by 6,155
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Wilkerson, M. D., & Hayes, D. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq170 · Cited by 5,645
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Self-citationMermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. M., Beroukhim, R., & Getz, G. A. (2011) · Genome biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,520
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
ClinVar: public archive of interpretations of clinically relevant variants
Landrum, M. J., Lee, J. M., Benson, M., Brown, G., Chao, C., Chitipiralla, S., Gu, B., Hart, J., Hoffman, D., Hoover, J., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1222 · Cited by 2,758
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Self-citationMassive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,000
The Evolution of Surgical Strategies for Pancreatic Neuroendocrine Tumors (Pan-NENs)
Landoni, L., Marchegiani, G., Pollini, T., Cingarlini, S., D’Onofrio, M., Capelli, P., Robertis, R. D., Davì, M. V., Amodio, A., Impellizzeri, H., et al. (2017) · Annals of Surgery · doi:10.1097/sla.0000000000002594 · Cited by 62
Self-citationFeola, T., Puliani, G., Sesti, F. F., Modica, R., Centello, R., Minotta, R., Cannavale, G., Meglio, S. D., Vito, V. D., Lauretta, R., et al. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01715-0 · Cited by 60
“In the inherited syndromes, such MEN1, MEN4, von Hippel-Lindau, the neurofibromatosis type 1, the genetic pathogenesis is well known, but also in sporadic NENs germline gene aberrations have been found [20, 21].”
BackgroundReceptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer
Sang, W., Zhou, Y., Chen, H., Yu, C., Dai, L., Liu, Z., Chen, L., Fang, Y., Ma, P., Wu, X., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0584 · Cited by 61
Hackeng, W. M., Schelhaas, W., Morsink, F. H. M., Heidsma, C. M., van Eeden, S., Valk, G. D., Vriens, M. R., Heaphy, C. M., van Dijkum, E. J. M. N., Offerhaus, G. J. A., et al. (2020) · Endocrine Pathology · doi:10.1007/s12022-020-09611-8 · Cited by 64
Eads, J. R., Halfdanarson, T. R., Asmis, T., Bellizzi, A. M., Bergsland, E. K., Dasari, A. N., El-Haddad, G. E., Frumovitz, M., Meyer, J. E., Mittra, E., et al. (2023) · Endocrine Related Cancer · doi:10.1530/erc-22-0206 · Cited by 62
April-Monn, S., Wiedmer, T., Skowronska, M., Maire, R., Lena, M. S., Trippel, M., Domenico, A. D., Muffatti, F., Andreasi, V., Capurso, G., et al. (2020) · Neuroendocrinology · doi:10.1159/000507669 · Cited by 59
Self-citationvan Treijen, M. J. C., Korse, C. M., van Leeuwaarde, R. S., Saveur, L. J., Vriens, M. R., Verbeek, W. H. M., Tesselaar, M. E. T., & Valk, G. D. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00740 · Cited by 57
Molecular Trajectory of BRCA1 and BRCA2 Mutations
Hatano, Y., Tamada, M., Matsuo, M., & Hara, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00361 · Cited by 58
Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms
Takayanagi, D., Cho, H., Machida, E., Kawamura, A., Takashima, A., Wada, S., Tsunoda, T., Kohno, T., & Shiraishi, K. (2022) · Cancers · doi:10.3390/cancers14051119 · Cited by 57
“The RADIANT-3 clinical trial with the mTOR inhibitor everolimus demonstrated its safety and efficacy in the treatment of advanced PANET [70].”
BackgroundInfluentialJiménez, C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00277 · Cited by 58
Neuroendocrine neoplasms of the pancreas: diagnosis and pitfalls
Konukiewitz, B., Jesinghaus, M., Kasajima, A., & Klöppel, G. (2021) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-021-03211-5 · Cited by 60
Paiella, S., Landoni, L., Rota, R., Valenti, M., Elio, G., Crinò, S. F., Manfrin, E., Parisi, A., Cingarlini, S., D’Onofrio, M., et al. (2020) · Endoscopy · doi:10.1055/a-1180-8614 · Cited by 57
“The biology of these tumors is complex [2] and there are currently few reliable markers of biological behavior.”
BackgroundSelf-citationWedge, M.-È., Jennings, V. A., Crupi, M. J. F., Poutou, J., Jamieson, T. R., Pelin, A., Pugliese, G., de Souza, C. T., Petryk, J., Laight, B. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29526-8 · Cited by 55
ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors
Chou, A. S. Y., Itchins, M., de Reuver, P. R., Arena, J., Clarkson, A., Sheen, A., Sioson, L., Cheung, V. K.-Y., Perren, A. A., Nahm, C. B., et al. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.07.032 · Cited by 55
“However, compared to many other studies including our own which generally show a combined incidence of ATRX/DAXX loss of no more than 43% [8,9,16,17], the 79% incidence of”
BackgroundResultSelf-citationHuman Beta Cell Regenerative Drug Therapy for Diabetes: Past Achievements and Future Challenges
Wang, P., Karaköse, E., Choleva, L., Kumar, K., DeVita, R. J., García-Ocaña, A., & Stewart, A. F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.671946 · Cited by 54
Young, K., Lawlor, R. T., Ragulan, C., Patil, Y., Mafficini, A., Bersani, S., Antonello, D., Mansfield, D., Cingarlini, S., Landoni, L., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-321016 · Cited by 53
Self-citationLakis, V., Lawlor, R. T., Newell, F., Patch, A., Mafficini, A., Sadanandam, A., Koufariotis, L. T., Johnston, R. L., Leonard, C., Wood, S., et al. (2021) · Communications Biology · doi:10.1038/s42003-020-01469-0 · Cited by 53
Self-citationUmetsu, S. E., Kakar, S., Baştürk, O., Kim, G., Chatterjee, D., Wen, K. W., Hale, G., Shafizadeh, N., Cho, S., Whitman, J., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2022.100065 · Cited by 60
Chauhan, A., Chan, K., Halfdanarson, T. R., Bellizzi, A. M., Rindi, G., O’Toole, D., Ge, P. S., Jain, D., Dasari, A. N., Anaya, D. A., et al. (2024) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21840 · Cited by 52
“31,32 The 5 ‐ year overall survival rates of patients who have pancreatic NETs based on pathologic stage are as follows: stage I, 92.98%; stage II, 91.86%; stage III, 85.18%; and stage IV, 53.59% (Figure 3C).”
BackgroundInfluentialThe evolving (epi)genetic landscape of pancreatic neuroendocrine tumours
Pipinikas, C., Berner, A., Sposito, T., & Thirlwell, C. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0175 · Cited by 52
“Germline mutations in MEN1 were also recently identified in sporadic PanNETs of apparently no familial history (Scarpa et al. 2017).”
BackgroundInfluentialMultilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors
Pedraza‐Arévalo, S., Gahete, M. D., Alors‐Pérez, E., Luque, R. M., & Castano, J. P. (2018) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-018-9465-0 · Cited by 51
Paulsson, J. O., Backman, S., Wang, N., Stenman, A., Crona, J., Thutkawkorapin, J., Ghaderi, M., Tham, E., Stalberg, P. L. H., Zedenius, J., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5359 · Cited by 52
“org/gatk (last accessed 19 August 2019)] and filtered for those with a possible protein effect in 96 cancer-associated genes [27] (supplementary material, Table S2).”
BackgroundSadowski, S. M., Pieterman, C. R. C., Perrier, N. D., Triponez, F., & Valk, G. D. (2020) · Endocrine Related Cancer · doi:10.1530/erc-19-0372 · Cited by 51
Heritable defects in telomere and mitotic function selectively predispose to sarcomas
Ballinger, M. L., Pattnaik, S., Mundra, P. A., Zaheed, M., Rath, E. M., Priestley, P., Baber, J., Ray-Coquard, I. L., Isambert, N., Causeret, S., et al. (2023) · Science · doi:10.1126/science.abj4784 · Cited by 49
Self-citationIyer, S., Modali, S. D., & Agarwal, S. K. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00278-17 · Cited by 50
“Chromatin-remodeling perturbations and concomitant transcriptional dysregulation as a consequence of MEN1 loss are now acknowledged as constituents of the genomic landscape of PNET pathogenesis and potential therapeutic targets (24, 48, 49).”
BackgroundThe Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?
Lamberti, G., Brighi, N., Maggio, I., Manuzzi, L., Peterle, C., Ambrosini, V., Ricci, C., Casadei, R., & Campana, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030747 · Cited by 51
“1) are lost in 70% of sporadic panNETs [78].”
BackgroundInfluentialYamasaki, K., Nakano, Y., Nobusawa, S., Okuhiro, Y., Fukushima, H., Inoue, T., Murakami, C., Hirato, J., Kunihiro, N., Matsusaka, Y., et al. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12593 · Cited by 50
Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management—An Updated Review
Bocchini, M., Nicolini, F., Severi, S., Bongiovanni, A., Ibrahim, T., Simonetti, G., Grassi, I., & Mazza, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00831 · Cited by 53
Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
Saghafinia, S., Homicskó, K., Domenico, A. D., Wullschleger, S., Perren, A. A., Marinoni, I., Ciriello, G., Michael, I. P., & Hanahan, D. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1637 · Cited by 51
“Then, to explore the predicted anti-correlation of MEIS2 and HMGB3 in human PanNETs, their expression was assessed in the human PanNET datasets (4,47,48).”
BackgroundMethodInfluentialComprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors
Sigal, D. S., Bhangoo, M. S., Hermel, J. A., Pavlick, D. C., Frampton, G. M., Miller, V. A., Ross, J. S., & Ali, S. M. (2018) · Oncotarget · doi:10.18632/oncotarget.26260 · Cited by 49
“We identified NTRK gene fusions in two pancreas NET patients despite the absence of these gene fusions among 102 pancreas NET patients screened with whole genome and RNA sequencing [4].”
BackgroundLiberini, V., Huellner, M. W., Grimaldi, S., Finessi, M., Thuillier, P., Muni, A., Pellerito, R. E., Papotti, M. G., Piovesan, A., Arvat, E., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10121083 · Cited by 53
Therapeutic targeting of tumor‐associated macrophages in pancreatic neuroendocrine tumors
Krug, S., Abbassi, R., Griesmann, H., Sipos, B., Wiese, D., Rexin, P., Blank, A., Perren, A. A., Haybaeck, J., Hüttelmaier, S., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31562 · Cited by 50
Two well-differentiated pancreatic neuroendocrine tumor mouse models
Wong, C. F., Tang, L. H., Davidson, C. J., Vosburgh, E., Chen, W., Foran, D. J., Notterman, D. A., Levine, A. J., & Xu, E. Y. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0355-0 · Cited by 48
Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms
Al‐Toubah, T., Halfdanarson, T. R., Gile, J. J., Morse, B. G., Sommerer, K. R., & Strosberg, J. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100364 · Cited by 48
“NETs are generally characterized by low tumor mutation burden (TMB), with identified mutations often involving chromatin remodeling genes such as DAXX/ATRX and MEN1.”
BackgroundSolid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway
Selenica, P., Raj, N. P., Kumar, R., Brown, D. N., Arqués, O., Reidy‐Lagunes, D. L., Klimstra, D. S., Snuderl, M., Serrano, J., Pálmer, H. G., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12490 · Cited by 46
“Furthermore, of the 328 pancreatic tumors included in the cBioPortal database (Bailey et al., 2018; Gao et al., 2013; Jiao et al., 2014; Scarpa et al., 2017; Wu et al., 2011) only 12 (3.”
BackgroundInfluentialGenomic profiling of NETs: a comprehensive analysis of the RADIANT trials
Yao, J. C., Garg, A. D., Chen, D., Capdevila, J., Engstrom, P. F., Pommier, R. F., Cutsem, E. V., Singh, S., Fazio, N., He, W., et al. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0332 · Cited by 50
Seplyarskiy, V. B., Akkuratov, E. E., Akkuratova, N., Andrianova, M. A., Nikolaev, S. I., Bazykin, G. A., Adameyko, I. I., & Sunyaev, S. R. (2018) · Nature Genetics · doi:10.1038/s41588-018-0285-7 · Cited by 46
When you’re strange: Unusual features of the MUTYH glycosylase and implications in cancer
Raetz, A. G., & David, S. S. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.05.005 · Cited by 48
“Notably, two genome-wide studies of pancreatic neuroendocrine [13] and adrenocortical [14] cancers (neither previously associated with MUTYH deficiency) found that tumors with a mutational spectrum dominated by G:C to T:A mutations were from heterozygous carriers of MAP variants, and further analysis confirmed a somat…”
BackgroundSalivary Gland Cancer in the Era of Routine Next-Generation Sequencing
Todorovic, E., Dickson, B. C., & Weinreb, I. (2020) · Head and Neck Pathology · doi:10.1007/s12105-020-01140-4 · Cited by 45
mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs)
Zanini, S., Renzi, S., Giovinazzo, F., & Bermano, G. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.562505 · Cited by 49
Alternative lengthening of telomeres is not synonymous with mutations in ATRX/DAXX
de Nonneville, A. T., & Reddel, R. R. (2021) · Nature Communications · doi:10.1038/s41467-021-21794-0 · Cited by 44
Self-citationVernieri, C., Pusceddu, S., Fucà, G., Indelicato, P., Centonze, G., Castagnoli, L., Ferrari, E., Ajazi, A., Pupa, S. M., Casola, S. S., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.32042 · Cited by 46
Telomere sequence content can be used to determine ALT activity in tumours
Lee, M., Teber, E., Holmes, O., Nones, K., Patch, A., Dagg, R. A., Lau, L. M. S., Lee, J. H. Y., Napier, C. E., Arthur, J. W., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky297 · Cited by 48
“Finally, we generated a RF classifier using both PanNETs and melanomas for the training set, to determine whether this approach would produce a more balanced classifier capable of predicting ALT +ve and ALT –ve tumours with comparable confidence (Figure 3C).”
BackgroundMethodInfluentialSelf-citationNeuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers
Herrera-Martínez, A. D., Hofland, L. J., Moreno, M. Á. G., Castano, J. P., de Herder, W. W., & Feelders, R. A. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0354 · Cited by 47
Cives, M., Partelli, S., Palmirotta, R., Lovero, D., Mandriani, B., Quaresmini, D., Pellè, E., Andreasi, V., Castelli, P., Strosberg, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55156-0 · Cited by 46
Self-citationDaxx maintains endogenous retroviral silencing and restricts cellular plasticity in vivo
Wasylishen, A. R., Sun, C., Moyer, S. M., Qi, Y., Chau, G. P., Aryal, N. K., McAllister, F. M., Kim, M. P., Barton, M. C., Estrella, J. S., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba8415 · Cited by 48
Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma
Ohmoto, A., Sato, Y., Asaka, R., Fukuda, N., Wang, X., Urasaki, T., Hayashi, N., Sato, Y., Nakano, K., Yunokawa, M., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00869-9 · Cited by 46
Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms
Yang, K., Kalloger, S. E., Aird, J. J., Lee, M. K. C., Rushton, C. K., Mungall, K. L., Mungall, A. J. J., Gao, D., Chow, C., Xu, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109817 · Cited by 48
Self-citationGastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models
Kawasaki, K., Fujii, M., & Sato, T. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.029595 · Cited by 45
“TSC is caused by mutations in TSC1 and TSC2, which encode the proteins tuberous sclerosis complex 1 and 2, respectively.”
BackgroundInfluentialChamberlain, C. E., German, M. S., Yang, K. Y., Wang, J., VanBrocklin, H. F., Regan, M., Shokat, K. M., Ducker, G. S., Kim, G., Hann, B. C., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1204 · Cited by 45
“Interestingly, PDX-PNETs harbored PTEN mutations and responded to mTOR inhibitor drugs ever-olimus and sapanisertib, suggesting that the PNET mutational pro fi le may determine drug response.”
InfluentialPrognostic Biomarkers in Pancreatic Cancer: Avoiding Errata When Using the TCGA Dataset
Nicolle, R., Raffenne, J., Paradis, V., Couvelard, A., de Reyniès, A., Blum, Y., & Cros, J. F. (2019) · Cancers · doi:10.3390/cancers11010126 · Cited by 45
“While these tumors are uncommon, they often fall under the umbrella term of “pancreatic cancer”, and are as such defined by completely different biology (mutational and transcriptional profiles) and clinical outcomes from the classical PDAC [2,3].”
BackgroundGatto, F., Barbieri, F., Arvigo, M., Thellung, S., Amarù, J., Albertelli, M., Ferone, D., & Florio, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163940 · Cited by 45
“Further studies will help clarify the reliability of PAS, alone or in combination with other agents [199,202], in the management of NETs.”
BackgroundInfluentialBlood-based next-generation sequencing analysis of neuroendocrine neoplasms
Zakka, K. M., Nagy, R. J., Drusbosky, L. M., Akce, M., Wu, C. S.-Y., Alese, O. B., El‐Rayes, B. F., Kasi, P. M., Mody, K., Starr, J. S., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27588 · Cited by 45
Xu, J., Ye, Z., Zhuo, Q., Gao, H., Qin, Y., Lou, X., Zhang, W., Wang, F., Wang, Y., Jing, D., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3599 · Cited by 46
Volante, M., Mete, Ö., Pelosi, G., Roden, A. C., Speel, E. M., & Uccella, S. (2021) · Endocrine Pathology · doi:10.1007/s12022-021-09668-z · Cited by 44
Jakobsdottir, G. M., Brewer, D. S., Cooper, C., Green, C., & Wedge, D. C. (2022) · BMC Biology · doi:10.1186/s12915-022-01316-0 · Cited by 43
Joseph, N. M., Umetsu, S. E., Kim, G. E., Terry, M., Perry, A., Bergsland, E. K., & Kakar, S. (2024) · Endocrine Pathology · doi:10.1007/s12022-024-09835-y · Cited by 43
Tirosh, A., Mukherjee, S., Lack, J., Gara, S. K., Wang, S., Quezado, M., Keutgen, X. M., Wu, X., Cam, M., Kumar, S., et al. (2019) · Cancer · doi:10.1002/cncr.31930 · Cited by 43
“Both PIP239 and DAG/ IP340 are involved in the phosphoinositide 3-kinase/ AKT/mammalian target of rapamycin pathway, which was reported by Scarpa et al17 as 1 of the 4 main pathways of NFPanNET pathogenesis.”
BackgroundSimon, T., Riemer, P., Detjen, K. M., Domenico, A. D., Bormann, F., Menne, A., Khouja, S., Monjé, N., Childs, L. H., Lenze, D., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01018-w · Cited by 45
“Group A tumors were all PanNETs and included all grades G1, G2, and G3 with mutated ATRX, DAXX ,and MEN1 (A-D-M) genotypes as well as known copy number patterns for PanNET tumors [69].”
BackgroundHigh glucose–induced ubiquitination of G6PD leads to the injury of podocytes
Wang, M., Hu, J., Yan, L., Yang, Y.-P., He, M., Wu, M., Li, Q., Gong, W., Yang, Y., Wang, Y., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201801921r · Cited by 36
Starr, J. S., Sonbol, M. B., Hobday, T. J., Sharma, A., Kendi, A. T., & Halfdanarson, T. R. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s202867 · Cited by 42
Wong, H., Yang, K., Shen, Y., Stutheit-Zhao, E. Y., Loree, J. M., Kennecke, H. F., Kalloger, S. E., Karasinska, J. M., Lim, H. J., Mungall, A. J. J., et al. (2017) · Molecular Case Studies · doi:10.1101/mcs.a002329 · Cited by 42
The Chromatin Remodeler ATRX: Role and Mechanism in Biology and Cancer
Pang, Y. K., Chen, X., Ji, T., Cheng, M., Wang, R., Zhang, C., Liu, M., Zhang, J., & Zhong, C. (2023) · Cancers · doi:10.3390/cancers15082228 · Cited by 46
“ALT activation is a multifactorial, cell-type-specific process, with ATRX/DAXX mutations being just one contributing factor [85–88].”
BackgroundInfluentialRecent Topics Around Multiple Endocrine Neoplasia Type 1
Marx, S. J. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02340 · Cited by 41
Inhibition of Wnt/β-Catenin Signaling in Neuroendocrine Tumors In Vitro: Antitumoral Effects
Jin, X., Spöttl, G., Maurer, J., Nölting, S., & Auernhammer, C. J. (2020) · Cancers · doi:10.3390/cancers12020345 · Cited by 45
“Our results in NET cells demonstrating only cell cycle inhibition, and no apoptosis, suggest that a combination of WNT974 with other molecular inhibitors or chemotherapy might be reasonable to effectively control NETs or other cancers [37,38].”
BackgroundInfluentialDual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker
Chan, D. L. H., Ulaner, G. A., Pattison, D. A., Wyld, D., Ladwa, R., Kirchner, J., Li, B. T., Lai, W. V., Pavlakis, N., ROACH, P. J., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.257659 · Cited by 41
Rapid and reversible suppression of ALT by DAXX in osteosarcoma cells
Yost, K. E., Soper, S. F. C., Walker, R. L., Pineda, M. A., Zhu, Y. J., Ester, C. D., Showman, S., Roschke, A. V., Waterfall, J. J., & Meltzer, P. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-41058-8 · Cited by 43
Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas
Patel, N. J., Barbieri, A., & Gibson, J. A. (2019) · Surgical pathology clinics · doi:10.1016/j.path.2019.08.007 · Cited by 40
Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors
Asa, S. L., Rosa, S. L., Baştürk, O., Adsay, V. N., Minnetti, M., & Grossman, A. B. (2021) · Endocrine Pathology · doi:10.1007/s12022-021-09662-5 · Cited by 41
“DAXX/ATRX are involved in histone modification/remodeling and telomere maintenance, and tumors with their mutually exclusive mutations have abnormal telomeres that are characteristic of a telomeraseindependent telomere maintenance mechanism termed “alternative lengthening of telomeres” (ALT) [86].”
BackgroundInfluentialRinke, A., Auernhammer, C. J., Bodei, L., Kidd, M. S., Krug, S., Lawlor, R. T., Marinoni, I., Perren, A. A., Scarpa, A., Sørbye, H., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-321300 · Cited by 40
Self-citationDual-molecular barcode sequencing detects rare variants in tumor and cell free DNA in plasma
Hirotsu, Y., Otake, S., Ohyama, H., Amemiya, K., Higuchi, R., Oyama, T., Mochizuki, H., Goto, T., & Omata, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-60361-3 · Cited by 38
The Mechanisms Underlying Autonomous Adrenocorticotropic Hormone Secretion in Cushing’s Disease
Fukuoka, H., Shichi, H., Yamamoto, M., & Takahashi, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239132 · Cited by 40
“In addition to the genetic alterations, epigenetic modification has been described, including DNA methylation and histone modifications [123,124].”
BackgroundNeuroendocrine neoplasms of the biliary tree, liver and pancreas: a pathological approach
Luchini, C., Pelosi, G., Scarpa, A., Mattiolo, P., Marchiori, D., Maragliano, R., Sessa, F., & Uccella, S. (2021) · Pathologica · doi:10.32074/1591-951x-231 · Cited by 39
Self-citationBlau, J. E., & Simonds, W. F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.623667 · Cited by 39
Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer
Sigal, D. S., Tartar, M., Xavier, M. F., Bao, F., Foley, P. J., Luo, D., Christiansen, J., Hornby, Z., Maneval, E. C., & Multani, P. S. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.7029 · Cited by 39
Boilève, A., Faron, M., Fodil-Cherif, S., Bayle, A., Lamartina, L., Planchard, D., Tselikas, L., Kanaan, C., Scoazec, J., Ducreux, M. P., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.03.024 · Cited by 38
Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors
Beyens, M., Vandamme, T., Peeters, M., Camp, G. V., & de Beeck, K. O. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0420 · Cited by 38
The tumor immune microenvironment in gastroenteropancreatic neuroendocrine neoplasms
Zhang, W.-H., Wang, W., Gao, H.-L., Yu, X., & Liu, L. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.188311 · Cited by 38
Boons, G., Vandamme, T., Mariën, L., Lybaert, W., Roeyen, G., Rondou, T., Papadimitriou, K., Janssens, K., de Beeck, B. O., Simoens, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2291 · Cited by 38
“The WGS data of the PNEN tissue samples (Dataset ID: EGAD00001002684) and PAAD tissue samples 201 (Dataset ID: EGAD00001003927) were available as BAM files (17,21).”
BackgroundMethodResultInfluentialKasajima, A., Pfarr, N., Mayr, E.-M., Ura, A., Moser, E., von Werder, A., Agaimy, A., Pavel, M., & Klöppel, G. (2024) · Endocrine Pathology · doi:10.1007/s12022-024-09827-y · Cited by 37
Oudijk, L., Gaal, J., & de Krijger, R. R. (2018) · Endocrine Pathology · doi:10.1007/s12022-018-9555-2 · Cited by 37
Lemelin, A., Barritault, M., Hervieu, V., Payen, L. F., Péron, J., Couvelard, A., Cros, J. F., Scoazec, J., Bin, S., Villeneuve, L., et al. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.02.001 · Cited by 37
Taşkın, O. Ç., Clarke, C. N., Erkan, M., Tsai, S., Evans, D. B., & Adsay, V. N. (2020) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2020.03.07 · Cited by 37
“07 closer to endocrine neoplasia, not showing association with glandular epithelial malignancies, and showing molecular/ genetic alterations of endocrine tumors like MEN1, Neurofibromatosis, or von-Hippel Lindau syndromes and not the molecular profile of ductal neoplasia (3,8-10).”
BackgroundExosomal miRNA signatures of pancreatic lesions
Vicentini, C., Calore, F., Nigita, G., Fadda, P., Simbolo, M., Sperandio, N., Luchini, C., Lawlor, R. T., Croce, C. M., Corbo, V., et al. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01287-y · Cited by 37
Self-citationWell Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review
Pellat, A., & Coriat, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061677 · Cited by 37
“Conversely, inactivating mutations in DAXX and ATRX and in MEN1 are exclusively found in pancreatic NET [17,18].”
BackgroundMelone, V., Salvati, A., Palumbo, D., Giurato, G., Nassa, G., Rizzo, F. M., Palo, L., Giordano, A., Incoronato, M., Vitale, M., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03511-7 · Cited by 37
Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?
Fazio, N., & Salvia, A. L. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101794 · Cited by 38
Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder
Liu, F., Li, Y., Ying, D., Qiu, S., He, Y., Li, M., Liu, Y., Zhang, Y., Hu, Y., Hu, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00412-3 · Cited by 36
Neuroendocrine Tumors: a Relevant Clinical Update
Rizen, E. N., & Phan, A. T. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01217-z · Cited by 36
MUTYH-associated tumor syndrome: The other face of MAP
Magrin, L., Fanale, D., Brando, C., Corsini, L. R., Randazzo, U., Piazza, M. D., Gurrera, V., Pedone, E., Russo, T. D. B., Vieni, S., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02304-y · Cited by 37
“Finally, a WGS analysis performed on a colon tumor from one MAP patient confirmed that, in addition to colon and duodenal tumors and a variety of extraintestinal cancers [9], MUTYH deficiency plays a role in PanNETs [20].”
BackgroundMethodInfluentialPancreatic Neuroendocrine Tumors: Update on the New World Health Organization Classification
Klöppel, G., Klimstra, D. S., Hruban, R. H., Adsay, V. N., Capella, C., Couvelard, A., Komminoth, P., Rosa, S. L., Ohike, N., OSAMURA, R. Y., et al. (2017) · AJSP Review and Reports · doi:10.1097/pcr.0000000000000211 · Cited by 37
Bodei, L., Raj, N. P., Do, R. K., Mauguen, A., Krebs, S. S., Reidy‐Lagunes, D. L., & Schöder, H. M. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264363 · Cited by 35
“These included 11q losses in 2 (grade 3 renal NET and mixed adenocarcinoma and small cell lung carcinoma) and 18q losses in 5 (3 small-bowel NETs, 2 rectal NETs).”
BackgroundInfluentialZhang, X., Fan, Y., Jing, R., Getu, M. A., Chen, W.-Y., Zhang, W., Dong, H., Dakal, T. C., Hayat, A., Cai, H.-J., et al. (2024) · Military Medical Research · doi:10.1186/s40779-024-00535-6 · Cited by 35
“Additionally, germline mutations have been observed in clinically sporadic pNETs, with genetic mutations identified in MUTYH , CHEK2 , and BRCA2 [33].”
BackgroundConemans, E. B., Lodewijk, L., Moelans, C. B., Offerhaus, G. J. A., Pieterman, C. R. C., Morsink, F. H. M., Dekkers, O. M., de Herder, W. W., Hermus, A. R. M. M., van der Horst‐Schrivers, A. N. A., et al. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0195 · Cited by 35
RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth
Umesalma, S., Kaemmer, C. A., Kohlmeyer, J. L., Letney, B. L., Schab, A. M., Reilly, J. A., Sheehy, R. M., Hagen, J., Tiwari, N., Zhan, F., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123049 · Cited by 35
Chromothripsis and DNA Repair Disorders
Nazaryan‐Petersen, L., Bjerregaard, V. A., Nielsen, F. C., Tommerup, N., & Tümer, Z. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030613 · Cited by 34
Aggressive versus indolent insulinomas: new clinicopathological insights
Hackeng, W. M., Brosens, L. A. A., & Dreijerink, K. M. A. (2023) · Endocrine Related Cancer · doi:10.1530/erc-22-0321 · Cited by 36
“In the previously mentioned series of insulinoma that identified ALT as a marker of aggressive behavior, ARX/PDX1 immunohistochemistry was also assessed (Hackeng et al. 2020) (Fig.”
BackgroundMethodInfluentialGriger, J., Widholz, S. A., Jesinghaus, M., Krätzig, N. D. A., Lange, S., Engleitner, T., Montero, J. J., Zhigalova, E., Öllinger, R., Suresh, V., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2023.06.001 · Cited by 35
Hoffman, S. E., Dowrey, T. W., Villacorta-Martín, C., Bi, K., Titchen, B. M., Johri, S., DelloStritto, L. K., Patel, M., MacKichan, C., Inga, S., et al. (2023) · Science Advances · doi:10.1126/sciadv.add9668 · Cited by 37
Self-citationFusion genes in pancreatic tumors
Γκουντάκος, Α., Singhi, A. D., Westphalen, C. B., Scarpa, A., & Luchini, C. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.01.009 · Cited by 36
Self-citation
Metadata
- Authors
- Initiative, A. P. C. G., Scarpa, A., Chang, D. K., Nones, K., Corbo, V., Patch, A.-M., Bailey, P., Lawlor, R. T., Johns, A. L., Miller, D. K., Mafficini, A., Rusev, B., Scardoni, M., Antonello, D., Barbi, S., Sikora, K. O., Cingarlini, S., Vicentini, C., McKay, S., Quinn, M. C. J., Bruxner, T. J. C., Christ, A. N., Harliwong, I., Idrisoglu, S., McLean, S., Nourse, C., Nourbakhsh, E., Wilson, P. J., Anderson, M. J., Fink, J. L., Newell, F., Waddell, N., Holmes, O., Kazakoff, S. H., Leonard, C., Wood, S., Xu, Q., Nagaraj, S. H., Amato, E., Dalai, I., Bersani, S., Cataldo, I., Dei Tos, A. P., Capelli, P., Davì, M. V., Landoni, L., Malpaga, A., Miotto, M., Whitehall, V. L. J., Leggett, B. A., Harris, J. L., Harris, J., Jones, M. D., Humphris, J., Chantrill, L. A., Chin, V., Nagrial, A. M., Pajic, M., Scarlett, C. J., Pinho, A., Rooman, I., Toon, C., Wu, J., Pinese, M., Cowley, M., Barbour, A., Mawson, A., Humphrey, E. S., Colvin, E. K., Chou, A., Lovell, J. A., Jamieson, N. B., Duthie, F., Gingras, M.-C., Fisher, W. E., Dagg, R. A., Lau, L. M. S., Lee, M., Pickett, H. A., Reddel, R. R., Samra, J. S., Kench, J. G., Merrett, N. D., Epari, K., Nguyen, N. Q., Zeps, N., Falconi, M., Simbolo, M., Butturini, G., Van Buren, G., Partelli, S., Fassan, M., Khanna, K. K., Gill, A. J., Wheeler, D. A., Gibbs, R. A., Musgrove, E. A., Bassi, C., Tortora, G., Pederzoli, P., Pearson, J. V., Waddell, N., Biankin, A. V., & Grimmond, S. M.
- Affiliations
- University of Verona (IT)
- Garvan Institute of Medical Research (AU)
- The University of Queensland (AU)
- Queensland University of Technology (AU)
- Glasgow Royal Infirmary (GB)
- Baylor College of Medicine (US)
- Children's Hospital at Westmead (AU)
- The University of Sydney (AU)
- Fremantle Hospital (AU)
- Royal Adelaide Hospital (AU)
- The University of Melbourne (AU)
- Corresponding author
- Scarpa, Aldo
- Biankin, Andrew V.
- Grimmond, Sean M.
- ORCID
- Scarpa, Aldo
- Chang, David K.
- Corbo, Vincenzo
- Patch, Ann-Marie
- Bailey, Peter
- Lawlor, Rita T.
- Johns, Amber L.
- Mafficini, Andrea
- Rusev, Borislav
- Antonello, Davide
- Barbi, Stefano
- Cingarlini, Sara
- Vicentini, Caterina
- Quinn, Michael C. J.
- Bruxner, Timothy J. C.
- Christ, Angelika N.
- Harliwong, Ivon
- Nourbakhsh, Ehsan
- Wilson, Peter J.
- Anderson, Matthew J.
- Fink, J. Lynn
- Newell, Felicity
- Holmes, Oliver
- Kazakoff, Stephen H.
- Leonard, Conrad
- Wood, Scott
- Nagaraj, Shivashankar Hiriyur
- Bersani, Samantha
- Cataldo, Ivana
- Davì, Maria Vittoria
- Landoni, Luca
- Malpaga, Anna
- Miotto, Marco
- Whitehall, Vicki L. J.
- Leggett, Barbara A.
- Harris, Jonathan
- Jones, Marc D.
- Chantrill, Lorraine A.
- Chin, Venessa
- Nagrial, Adnan M.
- Pajic, Marina
- Scarlett, Christopher J.
- Pinho, Andreia
- Rooman, Ilse
- Toon, Christopher
- Wu, Jianmin
- Pinese, Mark
- Cowley, Mark
- Barbour, Andrew
- Mawson, Amanda
- Colvin, Emily K.
- Chou, Angela
- Jamieson, Nigel B.
- Gingras, Marie-Claude
- Dagg, Rebecca A.
- Lau, Loretta M. S.
- Lee, Michael
- Pickett, Hilda A.
- Reddel, Roger R.
- Samra, Jaswinder S.
- Kench, James G.
- Merrett, Neil D.
- Nguyen, Nam Q.
- Zeps, Nikolajs
- Falconi, Massimo
- Simbolo, Michele
- Partelli, Stefano
- Fassan, Matteo
- Khanna, Kum Kum
- Gill, Anthony J.
- Wheeler, David A.
- Gibbs, Richard A.
- Bassi, Claudio
- Tortora, Giampaolo
- Pearson, John V.
- Waddell, Nicola
- Biankin, Andrew V.
- Grimmond, Sean M.
- Venue
- Nature
- Published
- 2017-02-15
- Volume
- 543
- Issue
- 7643
- Pages
- 65-71
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2589112207
- Cited by
- 999
- References
- 62
- Citations by year
- 2026: 65 · 2025: 101 · 2024: 103 · 2023: 110 · 2022: 126 · 2021: 108 · 2020: 131 · 2019: 89 · 2018: 103 · 2017: 52
- FWCI
- 81.15
- Type
- journal article
- Language
- en
- Update notices
- erratum (2017-09-27)
- Open access
- closed
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Pancreatic Cancer UK (RIF2015_A06_Jamieson, FLF2015_04_GLASGOW)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (23526, 17263, 22533)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- Medical Research Council (MR/N005813/1)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- pancreatic neuroendocrine tumors, mutational signatures, MUTYH, germline mutations, CHEK2, BRCA2, MEN1, VHL, chromatin remodeling, DNA repair, mTOR signaling, telomere maintenance, hypoxia, carcinogenesis
- MeSH terms
- Base Sequence, Calmodulin-Binding Proteins, Chromosome Aberrations, DNA Mutational Analysis, DNA Repair, Female, Humans, Male, Pancreatic Neoplasms, Genome, Human, RNA-Binding Proteins, Telomere, Germ-Line Mutation, Carcinoma, Neuroendocrine, Genomics, RNA-Binding Protein EWS, Chromatin Assembly and Disassembly, DNA Glycosylases, DNA Copy Number Variations, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
